Anti SCL -70 Antibody by ELISA
New
1,750.00₹
In stock
All over India
0 Reviews
### **Anti-Scl-70 Antibody by ELISA**
The **Anti-Scl-70 (anti-topoisomerase I) antibody ELISA test** is a blood assay used to diagnose systemic sclerosis (scleroderma).
* **Diagnostic Target:** It detects autoantibodies directed against the intracellular enzyme topoisomerase I (Scl-70).
* **Clinical Significance:** A positive result is highly specific for **diffuse cutaneous systemic sclerosis**, a severe subtype characterized by widespread skin thickening and rapid progression.
* **Risk Assessment:** Presence of these antibodies is strongly associated with an increased risk of severe internal organ involvement, particularly **interstitial lung disease (ILD)** and cardiac complications.
* **Methodology:** The Enzyme-Linked Immunosorbent Assay (ELISA) provides a rapid, quantitative measure of antibody levels to guide early therapeutic intervention.
The **Anti-Scl-70 (anti-topoisomerase I) antibody ELISA test** is a blood assay used to diagnose systemic sclerosis (scleroderma).
* **Diagnostic Target:** It detects autoantibodies directed against the intracellular enzyme topoisomerase I (Scl-70).
* **Clinical Significance:** A positive result is highly specific for **diffuse cutaneous systemic sclerosis**, a severe subtype characterized by widespread skin thickening and rapid progression.
* **Risk Assessment:** Presence of these antibodies is strongly associated with an increased risk of severe internal organ involvement, particularly **interstitial lung disease (ILD)** and cardiac complications.
* **Methodology:** The Enzyme-Linked Immunosorbent Assay (ELISA) provides a rapid, quantitative measure of antibody levels to guide early therapeutic intervention.
### **Anti-Scl-70 Antibody by ELISA**
The **Anti-Scl-70 (anti-topoisomerase I) antibody ELISA test** is a blood assay used to diagnose systemic sclerosis (scleroderma).
* **Diagnostic Target:** It detects autoantibodies directed against the intracellular enzyme topoisomerase I (Scl-70).
* **Clinical Significance:** A positive result is highly specific for **diffuse cutaneous systemic sclerosis**, a severe subtype characterized by widespread skin thickening and rapid progression.
* **Risk Assessment:** Presence of these antibodies is strongly associated with an increased risk of severe internal organ involvement, particularly **interstitial lung disease (ILD)** and cardiac complications.
* **Methodology:** The Enzyme-Linked Immunosorbent Assay (ELISA) provides a rapid, quantitative measure of antibody levels to guide early therapeutic intervention.
